The anti-MuSK subtype of MG presents a different response to immunomodulatory regimens compared to AchR MG, the proportion of patients with MuSK-MG requiring high doses and prolonged treatment to achieve full control of the disease seems to be higher (3–6). The gene discussed is MUSK; the disease is myasthenia gravis.